Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Halozyme Therapeutics Inc (NASDAQ:HALO)

19.57
Delayed Data
As of Dec 12
 +0.08 / +0.41%
Today’s Change
9.68
Today|||52-Week Range
19.95
+98.08%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Year
Trend

2013

2014

2015

2016
Revenue and IncomeNet Revenues54.8M75.3M135.1M146.7M
 
 
 
 
 
Cost of Goods Sold5.0M21.0M27.6M30.8M
 
 
 
 
 
Depreciation And Amortization1.2M1.8M1.7M2.4M
 
 
 
 
 
 
Operating ExpensesGross Income48.6M52.6M105.8M113.5M
 
 
 
 
 
General Expenses129.0M114.2M133.3M196.7M
 
 
 
 
 
Research And Development96.6M78.6M93.2M150.8M
 
 
 
 
 
Total Operating Expenses135.2M137.0M162.5M229.9M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-80.4M-61.6M-27.5M-83.2M
 
 
 
 
 
Extraordinary Charge0.00-1.4M0.000.00
 
 
Interest Expense On Debt3.3M5.6M5.2M20.0M
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-83.5M-68.4M-32.2M-101.9M
 
 
 
 
 
Income Taxes0.000.000.00-1.2M
 
 
Net Income-83.5M-68.4M-32.2M-103.0M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS112.8M122.7M126.7M128.0M
 
 
 
 
 
Shares To Calculate EPS Diluted112.8M122.7M126.7M128.0M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.74-$0.56-$0.25-$0.81
 
 
 
 
 
EPS Diluted-$0.74-$0.56-$0.25-$0.81